Century Therapeutics expects cash to support operations into 2H26
PremiumThe FlyCentury Therapeutics expects cash to support operations into 2H26
8d ago
Century Therapeutics sees FY24 GAAP operating expenses $150M-$160M
Premium
The Fly
Century Therapeutics sees FY24 GAAP operating expenses $150M-$160M
8d ago
Century Therapeutics Appoints Morgan Conn as New CFO
Premium
Company Announcements
Century Therapeutics Appoints Morgan Conn as New CFO
2M ago
Century Therapeutics Provides Investor Meeting Slide Update
PremiumCompany AnnouncementsCentury Therapeutics Provides Investor Meeting Slide Update
3M ago
Century Therapeutics reports Q2 EPS (38c), consensus (46c)
Premium
The Fly
Century Therapeutics reports Q2 EPS (38c), consensus (46c)
3M ago
Century Therapeutics files to sell 7.87M shares of common stock for holders
Premium
The Fly
Century Therapeutics files to sell 7.87M shares of common stock for holders
5M ago
Century Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
PremiumThe FlyCentury Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
6M ago
Century Therapeutics expects cash to support operations into 2026
Premium
The Fly
Century Therapeutics expects cash to support operations into 2026
6M ago
Century Therapeutics reports Q1 EPS (45c) vs. (53c) last year
Premium
The Fly
Century Therapeutics reports Q1 EPS (45c) vs. (53c) last year
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100